Ondansetron: Therapeutic Use as an Antiemetic

Drugs

Volumn 41, Issue 4, 1991, Pages 574-595

  Milne, Richard J ^a   Heel, Rennie C ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METOCLOPRAMIDE; ONDANSETRON; PLACEBO; SEROTONIN 3 RECEPTOR; SEROTONIN ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; BLOOD LEVEL; CAT; CLINICAL ARTICLE; CONGENITAL DISORDER; CONTROLLED STUDY; EXTRAPYRAMIDAL SYNDROME; GUINEA PIG; HUMAN; HUMAN EXPERIMENT; ILEUM; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; NONHUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT; RADIATION ENTEROPATHY; RAT; REVIEW; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; HUMAN; IMIDAZOLES; METOCLOPRAMIDE; NAUSEA; ONDANSETRON; RADIATION INJURIES; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; VOMITING;

ANIMALIA; CAVIA PORCELLUS; EMESIS; FELIS CATUS; ORYCTOLAGUS CUNICULUS; SUS SCROFA;

EID: 0025827739     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199141040-00006     Document Type: Article

References (101)

1. Antagonism of cisplatin-induced emesis by metoclopramide and dazopride through enhancement of gastric motility
2. 3 receptor in the anaesthetized ferret. Proceedings of the Physiological Society, 3–4 November 1989
3. The neurophysiology of vomiting
4. Neuropharmacology of emesis induced by anti-cancer therapy
5. 3 recognition sites within the human brainstem
6. 3 recognition sites in human brain tissue
7. 3 recognition sites
8. 3 recognition sites in the ferret area postrema
9. The clinical pharmacology of ondansetron
10. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy
11. Neuropharmacology of chemotherapy-induced emesis
12. High dorsal column cordotomy plus subdiaphragmatic vagotomy prevents acute ionizing radiation sickness in cats
13. Physiology and pharmacology of vomiting
14. Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Commentary
15. 3 receptors
16. Prevention of cyclophosphamide/cytarabine-induced emesis with ondansetron in children with leukemia
17. Differential modulation of three separate K-conductances in hippocampal CA1 neurons by serotonin
18. The determination in plasma and pharmacokinetics of ondansetron
19. 5-Hydroxytryptamine H-receptor antagonism to prevent cisplatin-induced emesis
20. 3-receptor antagonist on gastric emptying in the guinea-pig
21. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting
22. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens
23. 3 receptor antagonist
24. Ondansetron with and without dexamethasone to treat chemotherapy-induced emesis. Letter
25. Two distinct effects of 5-hydroxytryptamine on cortical neurons
26. Ondansetron compared with high dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting
27. Therapierefraktäre Emesis unter Cisplatin
28. Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy
29. 3 receptors and cytotoxic drug-induced vomiting
30. Two kinds of tryptamine receptor
31. Role of 5HT-3 receptor antagonists in gastrointestinal motility
32. Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist
33. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting
34. Correlation of anti-emetic efficacy and plasma levels of ondansetro
35. Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting
36. 3 receptors
37. Metoclopramide: an updated review of its pharmacological properties and clinical use
38. Dexamethasone can potentiate the anti-emetic action of a 5HT3 receptor antagonist on cyclophosphamide induced vomiting in the ferret
39. The role of the abdominal visceral innervation and 5-HT-M receptors in vomiting induced by the cytotoxic drugs cyclophosphamide and cisplatin in the ferret
40. GR 38Ö32F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis
41. 3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret
42. Metoclopramide-induced parkinsonism
43. Pharmacological characterization of 5-hydroxytryptamine-induced depolarization of the rat isolated vagus nerve
44. A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study
45. The anti-emetic efficacy, pharmacokinetics and safety of ondansetron in the elderly receiving cancer chemotherapy or radiotherapy. 15th International Cancer Congress (ICC), Hamburg, August 16–22, 1990. B4.252.09
46. Ondansetron for the prevention of emesis induced by highdose cisplatin. A multicenter dose-response study
47. 3 receptors in rat brain using radioligand binding
48. 3 H]GR65630, to rat area postrema, vagus nerve and the brains of several species
49. 3 receptor antagonists
50. Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy
51. Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin
52. Improved control of cisplatin-induced emesis with high-dose metoclopramide and combinations of metoclopramide, dexamethasone and diphenhydramine: results of consecutive trials in 255 patients
53. Extrapyramidal reactions with high-dose metoclopramide
54. Clinical phase I trial of SN-307 (ondansetron)
55. The properties of 5-HT3 receptors in clonal cell lines studied by patch-clamp techniques
56. Antiemetic efficacy and pharmacokinetic analyses of the serotonin antagonist ondansetron (GR 38032F) during multiple-day chemotherapy with cisplatin prior to autologous bone marrow transplantation
57. Prolonged metoclopramide-induced dyskinetic reaction
58. Evidence for presynaptic 5-hydroxytryptamine, recognition sites on vagal afferent terminals in the brainstem of the ferret
59. 3 receptors prevents cisplatin-induced but not motion- or xylazine-induced emesis in the cat
60. Randomized clinical trial of levonantrodol and chlorpromazine in the prevention of radiotherapy-induced vomiting
61. 3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting
62. 3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis
63. The effect of x-irradiation on 5-hydroxytryptamine (serotonin) contents in the small intestines of experimental animals
64. Cisplatin-induced vomiting eliminated by ablation of the area postrema in cats
65. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism
66. 3 receptors mediate cytotoxic drug and radiation-evoked emesis
67. New benzamide anti-emetics
68. 5-Hydroxytryptamine receptor subtypes
69. 3 antagonist ondansetron — an effective outpatient antiemetic in cancer treatment
70. 3 H]BRL 43694, binds to presynaptic sites in the nucleus tractus solitarius of the rat
71. 3 receptors in mammalian hindbrain
72. Clinical studies with ondansetron in the control of radiation-induced emesis
73. Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation
74. Influence of age and gender on the pharmacokinetics of ondansetron. Abstract
75. 2 receptors by different mechanisms
76. 3 receptors
77. 3 receptor binding sites in human dorsal vagal complex
78. 3 receptor antagonists
79. The metabolism of ondansetron
80. The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimes
81. 3-Rezeptor-Ant-agonist als Antiemetikum bei Zytostatika-induzierter Übelkeit und Erbrechen
82. Control by GR38032F of acute and delayed nausea (N) and vomiting (V) induced by non-cisplatin chemotherapy. Abstract
83. 3 antagonist GR38032F in the anti-emetic prophylaxis of patients receiving high-dose cisplatin chemotherapy
84. Ondansetron (GR38032F) plus dexamethasone: effective anti-emetic prophylaxis for patients receiving cytotoxic chemotherapy
85. Safety of ondansetron
86. 3-receptor antagonist, GR38032F
87. 3-receptor antagonist with anti-emetic properties
88. 3 antagonist (GR 38032F) on small intestinal transit and release of gastrointestinal peptides
89. 3 receptor antagonist, slows colonic transit in healthy man
90. Optimum management of nausea and vomiting in cancer chemotherapy
91. Pharmacological and antiemetic properties of ondansetron
92. Ondansetron in the prophylaxis of nausea and vomiting induced by cisplatin
93. Ondansetron — a new safe and effective antiemetic in patients receiving high-dose melphalan
94. Maintenance of anti-emetic effectiveness with multiple courses of GR 38032F and cisplatin
95. Three serotonin responses in cultured mouse hippocampal and striatal neurons